Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques

Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model

“…These results are similar to another recent study in which breakthrough viremia was also observed among at least 5/9 YF-VAX-immune cynomolgus macaques challenged with a low dose (∼1 LD 50 ) of YFV-Asibi. 44 In terms of protection against lethal infection, both HydroVax-YFV Pilot10 and YF-VAX vaccination conferred 100% protection ( p = 0.043 in each case, Mantel-Cox log-rank test; Figure 2 E) whereas HydroVax-YFV Pilot5 and HydroVax-YFV Pilot1 provided 75% and 50% protection, respectively ( p = 0.16, Mantel-Cox log-rank test; Figure 2 E).…”

“…The in vivo challenge experiments further supported 0.7 LNI as an acceptable immune correlate of protection and demonstrated that 20 NT 50 may also serve as a useful correlate of protective immunity against YF. The development of Vero cell-derived YF vaccines has several advantages over egg-based vaccine manufacturing of live-attenuated YF vaccines, 44 and the inactivated whole-virus vaccine approach described here is anticipated to have an improved safety profile with the potential for broader use in vulnerable populations including infants, the elderly, and those with compromised immune systems.…”